Core Viewpoint - The company has successfully completed a share buyback, resulting in a change in the shareholding structure of its controlling shareholder without altering control dynamics [2][5][10]. Buyback Approval and Plan - The company approved a share buyback plan on July 16 and August 6, 2025, allowing for the repurchase of shares at a price not exceeding 28.03 CNY per share, with a total fund allocation between 80 million and 120 million CNY [3][4]. - The buyback period is set from August 6, 2025, to August 5, 2026 [3]. Buyback Implementation - As of September 22, 2025, the company repurchased 5,472,559 shares, accounting for 0.98% of the total share capital, with a total expenditure of 120 million CNY [4][5]. - The buyback was executed in accordance with the disclosed plan, and the average repurchase price was 21.92 CNY per share [4][5]. Share Cancellation Arrangement - The repurchased shares will be canceled, reducing the registered capital of the company, and the cancellation process was initiated on September 24, 2025 [9][11]. - No objections were raised by creditors during the notification period regarding the share buyback [9]. Shareholding Changes - Following the cancellation of shares, the total number of shares will decrease from 556,890,744 to 551,418,185 [10]. - The controlling shareholder's stake will increase from 29.82% to 30.12% without any change in the number of shares held, thus not affecting the control of the company [2][10].

Core Viewpoint - Tai Chi Group (600129) announced the completion of its share repurchase on September 22, 2025, having repurchased a total of 5,472,559 shares, which represents 0.98% of the company's total share capital [1] Summary by Category - **Company Actions** - The company has successfully completed a share repurchase program, acquiring 5,472,559 shares [1] - The repurchased shares account for 0.98% of the total share capital of the company [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-073 重庆太极实业（集团）股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 重要内容提示： | | --- | | 回购方案首次披露日 | 2025/7/16，由董事会提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 月 2025 6 8 5 | 8 | 月 | 年 | 日 | | 预计回购金额 | 8,000万元~12,000万元 | | | | | | 回购价格上限 | 28.03元/股 | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 | | | | | | | □为维护公司价值及股东权益 | | | | | | 实际回购股数 | 5,472,559股 | | | | | | 实际回购股数占总股本比例 | 0.98% | | | | | | 实际回购金额 | 12,000.0 ...

Core Viewpoint - Taiji Group (600129.SH) has completed a share buyback, acquiring a total of 5.4726 million shares, which represents 0.98% of the company's total share capital [1] Summary by Categories Share Buyback Details - The company completed the buyback on September 22, 2025, with a maximum purchase price of 22.36 CNY per share and a minimum price of 21.46 CNY per share [1] - The average buyback price was 21.92 CNY per share, with a total expenditure of 120 million CNY, including transaction commissions and other fees [1]

Core Viewpoint - Tai Chi Group's stock has experienced a decline in both price and trading volume, reflecting a challenging financial performance in recent periods [1][2]. Group 1: Stock Performance - On September 22, Tai Chi Group's stock price fell by 2.03%, reaching 21.23 CNY per share, with a trading volume of 1.60 billion CNY and a market capitalization of 118.23 billion CNY [1]. - Year-to-date, the stock price has decreased by 14.12%, with a 1.80% drop over the last five trading days, a 10.46% decline over the last 20 days, and a slight decrease of 0.38% over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Tai Chi Group reported a revenue of 5.658 billion CNY, representing a year-on-year decrease of 27.63%, and a net profit attributable to shareholders of 139 million CNY, down 71.94% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 483 million CNY, with 167 million CNY distributed over the last three years [3]. Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 8.15% to 54,100, while the average circulating shares per person increased by 8.87% to 10,296 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 6.2524 million shares, a decrease of 880,600 shares, while the Southern CSI 1000 ETF is a new entrant with 3.6013 million shares [3].

Group 1 - The company, Chongqing Taiji Industrial (Group) Co., Ltd., will participate in the "Chongqing District 2025 Investor Online Collective Reception Day" event to enhance interaction with investors [1] - The event is scheduled for September 25, 2025, from 15:00 to 17:00, and investors can participate via the "Panjing Roadshow" website [1] - Company executives will engage in online communication with investors, addressing their concerns in a "one-to-many" format [1]

届时，公司相关高管人员将参加本次活动，通过网络在线交流形 式，就投资者所关心的问题，与投资者进行"一对多"形式的在线沟 通与交流。欢迎广大投资者踊跃参与。 证券代码：600129 证券简称：太极集团 公告编号：2025-072 重庆太极实业（集团）股份有限公司 关于参加"重庆辖区 2025 年投资者网上 集体接待日活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 为进一步加强与投资者的互动交流，重庆太极实业（集团）股份 有限公司（以下简称：公司）将参加由重庆证监局指导，重庆上市公 司协会联合深圳市全景网络有限公司举办的"重庆辖区上市公司2025 年投资者网上集体接待日活动"。 本次活动将于2025 年9 月25 日（星期四）下午15:00-17:00 举行， 投资者可登录"全景路演"网站（http://rs.p5w.net）参与本次活动。 特此公告。 重庆太极实业（集团）股份有限公司 2025 年 9 月 19 日 ...

Core Viewpoint - Tai Chi Group's stock has shown fluctuations with a recent increase of 2.21%, but the year-to-date performance indicates a decline of 10.15% [1] Financial Performance - For the first half of 2025, Tai Chi Group reported revenue of 5.658 billion yuan, a year-on-year decrease of 27.63%, and a net profit attributable to shareholders of 139 million yuan, down 71.94% [2] - Cumulative cash dividends since the A-share listing amount to 483 million yuan, with 167 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 8.15% to 54,100, while the average circulating shares per person increased by 8.87% to 10,296 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 880,600 shares, and new entrants such as Southern CSI 1000 ETF and Invesco Resource Monopoly Mixed A [3] Market Activity - The stock's trading volume reached 146 million yuan with a turnover rate of 1.20%, and the market capitalization stands at 12.369 billion yuan [1] - The net inflow of main funds was 8.2015 million yuan, with significant buying activity from large orders [1]

Core Viewpoint - The article discusses the recent approval of clinical trials for Semaglutide injection by Taiji Group's subsidiary, indicating a significant step in the GLP-1 drug market in China, which is currently dominated by Novo Nordisk's product. Group 1: Clinical Trial Approval - Taiji Group's subsidiary, Fuling Pharmaceutical Factory, has received the clinical trial approval notice from the National Medical Products Administration for Semaglutide injection [2] - The clinical trial is aimed at adult patients with type 2 diabetes who have not achieved blood sugar control despite using metformin and/or sulfonylureas, as well as those with cardiovascular diseases [6] Group 2: Market Competition - As of the announcement date, Novo Nordisk is the only company with an approved Semaglutide injection in China, generating significant revenue of $29.296 billion in 2024 [7] - Taiji Group's entry into the GLP-1 market signifies the emergence of new competition, with the company claiming advantages in quality and large-scale production through efficient yeast expression technology [7] Group 3: Research and Development Investment - The cumulative R&D investment for the Semaglutide project by Taiji Group is approximately RMB 44.1834 million (unaudited) [8] - Following the approval, Fuling Pharmaceutical Factory will initiate clinical trials and submit data to the regulatory authority for production and market approval [8] Group 4: Company Overview - Taiji Group is a large pharmaceutical manufacturing enterprise in China, involved in traditional Chinese medicine, chemical drugs, and active pharmaceutical ingredients [9] - The company's move into the GLP-1 target is viewed as a crucial step towards its transformation into modern biopharmaceuticals [9]

Group 1 - Junshi Bioscience's product Mindewei achieved full-channel coverage in the first half of 2025, exploring community and county market medical cooperation models [1] - Mindewei was conditionally approved for marketing by the National Medical Products Administration in January 2023, and the company has actively built a commercialization team [1] - The company has established strategic partnerships with national pharmaceutical companies and chain pharmacies, and is exploring sales models on platforms like Meituan, JD, and Alibaba Health [1] Group 2 - Changchun High-tech's subsidiary GS3-007a dry mixed suspension has received acceptance for its clinical trial application, aimed at treating pediatric growth hormone deficiency (PGHD) [2] - PGHD is a common endocrine disease in pediatrics, with an incidence rate of approximately 1 in 8600 in China, primarily caused by insufficient secretion of growth hormone-releasing hormone [2] Group 3 - Chengda Biologics has gained market access for its human rabies vaccine in Indonesia and is actively expanding into larger markets like Brazil [3] - The company's international business has shown significant growth, covering over 30 countries, and is advancing its "vaccine going abroad" strategy [3] Group 4 - Taiji Group's subsidiary has received clinical trial approval for semaglutide injection, targeting blood sugar control in adults with type 2 diabetes [4] - The indication includes patients whose blood sugar remains uncontrolled despite diet and exercise, and those at risk of major cardiovascular events [4] Group 5 - China National Pharmaceutical Group plans to strengthen accounts receivable management and establish a tracking ledger for key customers [5] - The company reported a net cash flow of -546 million yuan in the first half of 2025, a significant improvement from -743 million yuan in the same period last year [5] Group 6 - Zhend Medical expects its African production base to break even by the end of the year while actively advancing the construction of its Mexican production base [6][7] - The company is focusing on expanding into emerging markets with increasing demand for basic medical supplies and is enhancing operational efficiency in its African base [6][7]